Adaptimmune, March 18th

Speaker Biography

Adrian (Ad) Rawcliffe, Chief Executive Officer
Adrian (Ad) Rawcliffe has served as our Chief Executive Officer since September 2019 and is a member of our Executive Team. Previously, he served as our Chief Financial Officer from March 2015 through September 2019.

Mr. Rawcliffe has over 20 years of experience within the biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. He joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture‑capital business. Mr. Rawcliffe currently serves as a non‑executive director of WAVE Life Sciences (NASDAQ: WVE).

Mr. Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.

About

The personal nature of our science and our drive is supported by the perseverance to successfully discover, develop and commercialize cell therapies.
Our drive is to redefine the treatment of some of the most challenging-to-treat solid tumors. Our proprietary cell therapy platform engineers a patient’s own cells to fight cancer.

Our robust pipeline of cell therapies has the potential to significantly improve the patient’s treatment experience.

Adaptimmune delivers on this personalized approach from discovery through delivery with fully integrated capabilities including research, global clinical development, translational sciences, commercialization and manufacturing.